col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


44 Results       Page 1

 [1] 
Informa UK (Taylor & Francis): Journal of Medical Economics
  original article Date Title Authors   All Authors
1 [GO] 2026―Jun―13 Potential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective Jennifer Benner, Jackie Lee, Laura Cianciolo, Tendai Mugwagwa, Alfonso de Lossada, Carmen Peral, Matthew Sussman
2 [GO] 2026―Jun―08 Modeling the cost-effectiveness of the COVID-19 mRNA-1273 vaccine in the United States Kelly Fust, Ekkehard Beck, Michele Kohli, Shannon Cartier, Nicolas Van de Velde, Milton Weinstein, Keya Joshi
3 [GO] 2026―Mar―27 Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States Alon Yehoshua, Manuela Di Fusco, Abby E. Rudolph, Elizabeth Thoburn, Santiago M. C. Lopez, Josie Dodd, Benjamin Yarnoff
4 [GO] 2026―Mar―24 Estimating the public health and economic impact of increased COVID-19 annual vaccination coverage in the 60 years and older population in Spain Santiago Moreno Guillén, Esther Redondo Margüello, Juan Rodríguez García, Susana Aceituno, Miriam Prades, Jingyan Yang, et al. (+3)
5 [GO] 2026―Mar―17 The full value of mRNA seasonal influenza and endemic-stage COVID-19 combination vaccines: a taxonomy J. P. Sevilla, Joseph S. Knee, Daria Burnes, Genevieve Meier, Jingyan Yang, Manuela Di Fusco, et al. (+2)
6 [GO] 2026―Mar―05 Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States Kelly Fust, Michele Kohli, Keya Joshi, Shannon Cartier, Amy Lee, Nicolas Van de Velde, et al. (+2)
7 [GO] 2026―Jan―22 Incorporating underreporting of epidemiological burden in COVID-19 models: a targeted literature review Ishveen Chopra, Jingyan Yang, Alon Yehoshua, Carlos Fernando Mendoza, Manuela Di Fusco
8 [GO] 2025―Dec―27 Annual vaccination with BNT162b2 in Germany can avoid substantial clinical and economic burden of COVID-19 disease Amy Barber, Julie Roiz, Sam Greenall, Edward Church, Andrea Schmetz, Stefan Riebel, et al. (+3)
9 [GO] 2025―Dec―13 Comparison of work productivity losses in the United States among employees with COVID-19 at high-risk of severe disease who were untreated or treated with nirmatrelvir/ritonavir Maria M. Fernandez, Brenna L. Brady, Kristin A. Evans, Gurinder S. Sidhu, Paul Cislo, Frank R. Ernst, et al. (+4)
10 [GO] 2025―Oct―24 Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review Tendai Mugwagwa, José Marcano Belisario, Louise Hartley, Nguyen Thi Nhan Phan
11 [GO] 2025―Aug―19 The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada Kelly Fust, Michele Kohli, Shannon Cartier, Keya Joshi, Nicolas Van de Velde, Ekkehard Beck, Michelle Blake
12 [GO] 2025―Jul―25 Economic evaluation of oral Nirmatrelvir/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany: a cost-effectiveness analysis Constanze Schmalhofer, Eveline Otte im Kampe, Dirk Eheberg, Hera Sandhu, Martina Maier, Alexander Perschke, et al. (+3)
13 [GO] 2025―Jun―27 Quantifying all-cause healthcare resource utilization and costs of children with mild-to-moderate long COVID in France Jingyan Yang, Cheikh Tamberou, Elise Arnee, Pierre-Alexandre Squara, Ayoub Boukhlal, Jennifer L. Nguyen, et al. (+7)
14 [GO] 2025―Mar―31 Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada - a matched, population-based observational study Christina Qian, Karissa M. Johnston, Maria Tinajero, M. Lauren Voss, Austin Nam, Mackenzie A. Hamilton
15 [GO] 2025―Feb―20 US consumer and healthcare professional preferences for combination COVID-19 and influenza vaccines Christine Poulos, Philip O. Buck, Parinaz Ghaswalla, Deborah Rudin, Cannon Kent, Darshan Mehta
16 [GO] 2025―Jan―31 Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population Ataru Igarashi, Kenji Kurazono, Naoya Itsumura, Tomomi Takeshima, Kosuke Iwasaki
17 [GO] 2024―Dec―20 Cost-effectiveness of outpatient COVID-19 antiviral treatment with Nirmatrelvir/Ritonavir versus usual care in Swedish patients with various risk factors. Fredrik Nilsson, Martina Aldvén, Christian Gerdesköld Rappe, Tendai Mugwagwa
18 [GO] 2024―Nov―13 Public health and economic impact of COVID-19 vaccination with the Pfizer-BioNTech COVID-19 Vaccine, KP.2, among adults in 2024/2025 in the United States Alon Yehoshua, Manuela Di Fusco, Abby E. Rudolph, Elizabeth Thoburn, Santiago M.C. Lopez, Kinga Marczell, Benjamin Yarnoff
19 [GO] 2024―Oct―31 The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA autumn 2024 vaccines in the United Kingdom Michele A. Kohli, Michael Maschio, Amy Lee, Keya Joshi, Stuart Carroll, Orsolya Balogh, et al. (+2)
20 [GO] 2024―Oct―21 Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineages Alon Yehoshua, Angela D. Cook, Manuela Di Fusco, Abby E. Rudolph, Elizabeth Thoburn, Santiago M.C. Lopez, et al. (+2)
21 [GO] 2024―Sep―04 Comparison of healthcare resource use and cost between influenza and COVID-19 vaccine coadministration and influenza vaccination only Darshan Mehta, Tianyu Sun, Jane Wang, Aaron Situ, Yoonyoung Park
22 [GO] 2024―Jul―10 Impact of COVID-19 on Work Loss in the United States- A Retrospective Database Analysis Jennifer Judy, Alon Yehoshua, Julie Gouveia-Pisano, Richard A. Brook, Nathan L. Kleinman, Alek A. Drnach, et al. (+6)
23 [GO] 2024―Jan―31 Economic burden of COVID-19 for employers and employees in the United States Heather Sell, Kassandra Schaible, Julie A. Gouveia-Pisano, Alon Yehoshua, Deepa Malhotra, Manuela Di Fusco, et al. (+6)
24 [GO] 2023―Dec―05 Clinical impact and cost-effectiveness of the updated COVID-19 mRNA autumn 2023 vaccines in Germany K Joshi, S Scholz, M Maschio, M Kohli, A Lee, K Fust, et al. (+3)
25 [GO] 2023―Nov―28 COVID-19 vaccines should be evaluated from the societal perspective J P Sevilla
26 [GO] 2023―Nov―15 The impact of vaccination and outpatient treatment on the economic burden of covid-19 in the United States omicron era: a systematic literature review Vicki Pierre, Florin Draica, Manuela Di Fusco, Jingyan Yang, Solange Nunez-Gonzalez, Joanna Kamar, et al. (+9)
27 [GO] 2023―Nov―14 The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States Michele A. Kohli, Michael Maschio, Keya Joshi, Amy Lee, Kelly Fust, Ekkehard Beck, et al. (+2)
28 [GO] 2023―Sep―22 Burden of COVID-19 during the omicron predominance in Brazil: a nationwide retrospective database study Jingyan Yang, Guilherme Cordeiro, Mauricio Longato, Shailja Vaghela, Moe H. Kyaw, Carlos Fernando Mendoza, et al. (+4)
29 [GO] 2023―Jun―09 The role of machine learning in healthcare responses to pandemics: maximizing benefits and filling gaps Ahmad Z. Al Meslamani, Anan S. Jarab, Mohammad A. Ghattas
30 [GO] 2023―Mar―21 Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5) in the United States Manuela Di Fusco, Kinga Marczell, Elizabeth Thoburn, Timothy L. Wiemken, Jingyan Yang, Benjamin Yarnoff
31 [GO] 2023―Feb―22 Burden of illness associated with overweight and obesity in patients hospitalized with COVID-19 in the United States: analysis of the premier healthcare database from April 1, 2020 to October 31, 2020 Nina Kim, Abdalla Aly, Chris Craver, W. Timothy Garvey
32 [GO] 2022―Oct―03 The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States Michele A. Kohli, Michael Maschio, Amy Lee, Kelly Fust, Nicolas Van de Velde, Philip O. Buck, Milton C. Weinstein
33 [GO] 2022―Sep―13 Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021 Diana Mendes, Ruth Chapman, Peter Gal, Jessica Atwell, Jennifer L. Nguyen, Libby Hamson, et al. (+3)
34 [GO] 2022―May―16 Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States Manuela Di Fusco, Kinga Marczell, Kristen A. Deger, Mary M. Moran, Timothy L. Wiemken, Alejandro Cane, et al. (+4)
35 [GO] 2022―Apr―07 Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19 Scott Gibson, Rhodri Saunders, Nathan Stasko, Cherrishe-Brown Bickerstaff, John Oakley, Mark Osterman, et al. (+4)
36 [GO] 2022―Mar―16 COVID-19-associated hospitalizations among children less than 12 years of age in the United States Manuela Di Fusco, Shailja Vaghela, Mary M. Moran, Jay Lin, Jessica E. Atwell, Deepa Malhotra, et al. (+4)
37 [GO] 2022―Mar―15 How China controls the Covid-19 epidemic through public health expenditure and policy? Hui Jin, Baoyang Li, Mihajlo Jakovljevic
38 [GO] 2022―Feb―04 Real-world retrospective analysis of patient characteristics, healthcare resource utilization, costs, and treatment patterns among unvaccinated adults with COVID-19 diagnosed in outpatient settings in the United States Amie Scott, Richard Chambers, Maya Reimbaeva, Jessica Atwell, Nathalie Baillon-Plot, Florin Draica, Miriam Tarallo
39 [GO] 2022―Jan―17 Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective Adrian Kilcoyne, Edward Jordan, Allen Zhou, Kimberly Thomas, Alicia N. Pepper, Dale Chappell, et al. (+3)
40 [GO] 2022―Jan―06 The societal economic value of COVID-19 vaccines in the United States Noam Kirson, Elyse Swallow, Jessica Lu, Marco Mesa-Frias, Brahim Bookhart, Josie Maynard, et al. (+2)
41 [GO] 2021―Nov―30 Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2 Manuela Di Fusco, Mary M. Moran, Alejandro Cane, Daniel Curcio, Farid Khan, Deepa Malhotra, et al. (+5)
42 [GO] 2021―Aug―06 Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis William V. Padula, Shreena Malaviya, Natalie M. Reid, Benjamin G. Cohen, Francine Chingcuanco, Jeromie Ballreich, et al. (+2)
43 [GO] 2021―Feb―13 Health outcomes and economic burden of hospitalized COVID-19 patients in the United States Manuela Di Fusco, Kimberly M Shea, Jay Lin, Jennifer L Nguyen, Frederick J Angulo, Michael Benigno, et al. (+6)
44 [GO] 2020―Nov―30 Iran, sanctions, and the COVID-19 crisis Amir Abdoli
 [1] 

44 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.004 sec